Groupe d'Etude en Oncologie du Quebec

Titre	A Phase 1b/2, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation
Protocole ID	20190135 (CodeBreak 101)
ClinicalTrials.gov ID	NCT04185883
Type(s) de cancer	Tumeurs solides
Phase	Phase I-II
Stade	Maladie avancée ou métastatique
Type étude	Clinique
Médicament	Sotorasib en monothérapie et en association avec d'autres thérapies
Institution	L'HOTEL-DIEU DE QUEBEC ET CRCEO 11 Côte du Palais, Québec, QC, G1R 2J6
Ville	Québec
Investigateur(trice) principal(e)	Dr Maxime Chénard-Poirier
Coordonnateur(trice)	Maryse Gingras 418-691-5781
Statut	Actif en recrutement
Critètes d'éligibilité	Men or women greater than or equal to 18 years old. Pathologically documented, locally-advanced or metastatic malignancy with, KRAS p.G12C mutation identified through molecular testing performed according to in-country requirements.
Critètes d'exclusion	Primary brain tumor. Spinal cord compression, or untreated, or symptomatic, or active brain metastases, or leptomeningeal disease from non-brain tumors. Myocardial infarction within 6 months of study day 1. Gastrointestinal (GI) tract disease causing the inability to take oral medication.

Groupe d'étude en oncologie du Québec